Penumbra – Consensus Indicates Potential 13.1% Upside

Broker Ratings
[shareaholic app="share_buttons" id_name="post_below_content"]

Penumbra found using ticker (PEN) now have 7 analysts in total covering the stock. The consensus rating is ‘Buy’. The range between the high target price and low target price is between 260 and 163 calculating the average target price we see 195.71. With the stocks previous close at 173.06 this now indicates there is a potential upside of 13.1%. The 50 day MA is 134.64 and the 200 day moving average is 200.05. The company has a market capitalisation of $6,435m. Visit the company website at: https://www.penumbrainc.com

The potential market cap would be $7,278m based on the market concensus.

Penumbra designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers aspiration based thrombectomy systems and accessory devices, including revascularization device for mechanical thrombectomy, such as Penumbra System under the Penumbra RED, JET, ACE, 3D Revascularization Device, and Penumbra ENGINE brands, as well as components and accessories; neurovascular embolization coiling systems to treat patients with various sizes of aneurysms and other neurovascular lesions under the Penumbra Coil 400, POD400, PAC400, and Penumbra SMART Coil brand names; and neurovascular access systems designed to provide intracranial access for use in a range of neurovascular therapies under the Neuron, Neuron MAX, Select, BENCHMARK, BMX96, DDC, and PX SLIM brands. It also provides neurosurgical aspiration tools for the removal of tissue and fluids under the Artemis Neuro Evacuation Device brand; aspiration-based thrombectomy systems for vascular applications under the Indigo System brand; and detachable embolic coil systems for peripheral embolization under the Ruby Coil and Ruby LP brand names. In addition, the company offers microcatheter for the delivery of detachable coils and occlusion devices under the LANTERN brand; and detachable, microcatheter-deliverable occlusion devices designed primarily to occlude peripheral vessels under the POD (Penumbra Occlusion Device) brand, as well as immersive computer-based technologies and immersive therapeutics to promote health, motor function, and cognition under the Real Immersive System brand; and a complementary device for use with Ruby Coil and POD for vessel occlusion under the Packing Coil and Packing Coil LP brands. The company sells its products through direct sales organizations and distributors. Penumbra was incorporated in 2004 and is headquartered in Alameda, California.

Twitter
LinkedIn
Facebook
Email
Reddit
Telegram
WhatsApp
Pocket
Find more news, interviews, share price & company profile here for:
Pennant International Group plc forecasts robust FY24 results and launches its Auxilium software suite, focusing on high-margin growth and restructuring.
Pennant International (LON:PEN) appoints Darren Wiggins as permanent CFO, leveraging his expertise for strategic growth in the software-focused sector.
Pennant International (LON:PEN) announces significant contracts, including a £4.9M RAF upgrade and new software and service deals in North America.

Search

Search